BioWorld Today here continues its occasional listings of governmentagencies seeking industrial licensees to commercialize their biotech-related research and development inventions. Commercializationrights are offered by the National Institutes of Health, Office ofTechnology Transfer (OTT). Announcements of the followingopportunities will be published imminently in the Federal Register.

To obtain licensing information, and copies of the pending U.S.patent applications listed below, contact OTT licensing specialistsindicated.

National Cancer Institute

Avian Retroviral Vectors Facilitate Gene Transfer

Avian sarcoma leukosis viruses have envelope gene derived frommammalian retrovirus, which permits high-titer viral stocks to beprepared in avian cells. Resulting vector is replication-defective inmammalian _ including human _ cells, permitting efficient genetherapy.

Application: 08/445, 462

Filed: 5/22/95

Inventors: Barsov, E., et al.

Contact: Larry Tiffany, (301) 496-7056, ext. 206

DNA Construct Selectively Ousts Undesired Cell Types

Sequence expresses modified bacterial cytosine deaminase (CD) genein mammalian cells. CD can convert 5-fluorocytosine (5-FC) to 5-fluorouracil, a cytotoxic antimetabolite. Cells transformed with theDNA construct can be selectively killed by treatment with 5-FC.Potential uses include gene therapy, immunotherapy, bone-marrowtransplants.

U. S. Patent No. 5,358,866

Issued: 11/25/94

Inventors: Blaese, R. M., et al.

Contact: Larry Tiffany, (301) 496-7056, ext. 206

Leucine Zipper Regulates Protein Transcription

Dominant negative transcription factors, modified to increasestability of dimerization reaction between leucine zipper regions ofbasic-region zipper proteins, can inhibit DNA binding andtransactivation, thus preventing production of detrimental genes andproteins.

Application: 60/001/654

Filed: 7/31/95

Inventor: Vinson, C. R.

Contact: Allan Kiang, (301) 496-7735, ext. 270

Early Detection Of HIV Infection, Antigens

Diagnostic measures activation of peripheral blood mononuclear cellsafter incubation with synthetic HIV epitopes. Detects exposure tovirus before seroconversion, sooner than current antibody tests, PCRamplification of viral DNA. Especially useful to screen donor bloodsupply.

Application: 08/488/435

Filed: 6/7/95

Inventors: Shearer, G. M., et al.

Contact: George Keller, (301) 496-7735, ext. 246

New Herpes Virus Isolated

Human Herpes Virus Type 6 (HHV-6) _ formerly, Human BLymphotropic Virus (HBLV) _ causes common childhood disease,roseola, linked to multiple sclerosis and diseases in immunodeficientpersons, including HIV-infected. Claims cover HHV-6 virus, its genesequences and expression products, infected cell cultures, detectionmethods.

Application: 08/392,674 (Granted in Europe)

Filed: 2/22/95

Inventors: R. C. Gallo, et al.

Contact: George Keller, (301) 496-7735, ext. 246

Antisense Oligos Block Kaposi Lesions

Unique antisense oligonucleotides bind basic fibroblast growth factorwith high affinity, inhibit progression of Kaposi's sarcoma cells inAIDS patients. Includes method of administering treatment,monitoring progress.

Application: 08/463/978

Filed: 6/5/95

Inventors: R. C. Gallo, et al.

Contact: Cindy K. Fuchs, (301) 496-7735, ext. 232

Liver Cancer Diagnosis, Therapy, Screening

Hepatocellular carcinoma has high incidence in Asia, particularlyamong hepatitis carriers. Amplified gene expression product ofhepatoma is an oncogene (i.e., transforming sequence), of which theantibody, or the cDNA itself, can be used for diagnostic, therapeuticand screening tests.

Application: 08/471,540

Filed: 6/6/95

Inventor: S. S. Yang.

Contact: Ken Hemby, (301) 496-7735, ext. 265

Enhanced Immun e Response To Infection, Cancer

Newly isolated human leukocyte-derived peptides exhibit potentmonocyte chemotaxis, for enhancing immune response to variety ofinfections, malignancies.

Application: 08/449,552

Filed: 5/24/95

Inventors: Yoshimura, T., et al.

Contact: Jaconda Wagner, (301) 496-7735, ext. 284

Reversing Methotrexate Resistance

Multi-purpose cancer chemotherapeutic agent, methotrexate (MTX),confronts frequent emergence of tumor-cell resistance. Increasedexpression of reduced folate carrier protein via gene therapy canrestore cellular sensitivity to MTX.

Application: 08/484,840

Filed: 6/7/95

Inventors: Moscow, J., et al.

Contact: Allan Kiang, (301) 496-7735, ext. 270

Early Detection Of Breast Cancer

Protein binds specifically to promoter region of highly oncogenic. c-ERBB2 (HER-2/neu) gene. Antibody to it assays for protein'spresence in biological sample, thus detects cancer earlier than currentmethods. Protein can also test efficacy of candidate inhibitory drugs.

Application: 08/229/515

Filed: 4/19/9 4

Inventors: Raziuddin and Sarkar, F.

Contact: Susan Rucker, (301) 496-7735, ext. 245

National Institute On Aging

Two-Edged Gene To Suppress Tumors, Boost Cell Growth

Prohibitin, a negative regulatory gene, when mutated, leads to celldeath (apoptosis), so may act as tumor suppressor. Its inactivationmay correct insufficient cellular proliferation, as in osteoporosis,poor wound healing.

Application: 08/466,762

Filed: 6/5/95

Inventors: Nuell, M. J., et al.

Contact: Ken Hemby, (301) 496-7056, ext. 265

National Institute of Allergy & Infectious Diseases

Protein Against Emphysema, Cirrhosis, Liver Cancer

Gene expressing first known protein capable of inhibiting serineproteases, to treat conditions such as emphysema, cirrhosis, livercancer.

U. S. Patent # 5,187,268

Issued: 2/16/93

Inventors: Moss, B., et al.

Contact: Carol Lavrich, (301) 496-7735, ext. 287

High-Potency Anti-HIV-1 Antibody

Soluble viral envelope protein, gp140 is a recombinant version ofgp160, but conserves the parent protein's quaternary structure. Thus,antibodies raised against it "may be more broadly reactive againstvarious forms of AIDS than other antibodies generated to date."

Application: 08/165,314

Filed: 10/12/93

Inventors: Moss, B., et al.

Contact: Cindy K. Fuchs, (301) 496-7735, ext. 232

National Heart, Lung & Blood Institute

Improved Retroviral Vectors For Gene Therapy

Complement system's C1 subcomponents and antibody fragmentsprotects retroviral vector particles produced in non-primatepackaging lines from attack by primate complement cascade in vivo.

Application: 08/098,944

Filed: 7/28/93

Inventor: Mason, J. M., et al.

Contact: Carol Lavrich, (301) 496-7735, ext. 287

Protein Expression In Human Gut

Unlike alternative delivery systems, e.g., retroviral vectors, methoddirectly transfers gene of interest to targeted cells in gastrointestinaltract _ whether dividing or not. Permits systemic long-termadministration of therapeutic protein to a patient, avoiding periodicinjections, suppositories.

Application: 07/776,057

Filed: 10/16/91

Inventor: Crystal, Ron

Contact: Larry Tiffany, (301) 496-7056, ext. 206

CombiChem Signs First Deal With Japan Drug Maker

CombiChem Inc., a start-up combinatorial chemistry company,signed its first major corporate collaboration worth more than $10million with Japan-based Teijin Ltd.

La Jolla, Calif.-based CombiChem will apply its technology to createlibraries of potential therapeutic compounds based on a leadmolecule provided by Teijin. The Osaka-based pharmaceutical firmis seeking compounds that act as antagonists to a particular G-proteincoupled receptor subtype.

G-protein receptors are responsible for transferring into cells externalsignals that regulate cellular activity and are potential drug targets formany diseases.

Peter Myers, CombiChem's chief scientific officer and chiefoperating officer, said specifics of the drug discovery program werenot disclosed.

CombiChem will receive up-front funds and milestone paymentstotaling more than $10 million, but details were not revealed. Thecompany also would receive royalties on compounds that aremarketed. The agreement did not involve an equity investment byTeijin.

CombiChem was founded in 1994 with technology licensed fromSydney Brenner, a member of the Scripps Research Institute in LaJolla and an honorary professor of genetic medicine at the Universityof Cambridge in England. (See BioWorld Today, Jan. 20, 1995, p.2.) _ Charles Craig

-- David N. Leff Science Editor

(c) 1997 American Health Consultants. All rights reserved.